Chemoimmunotherapy

Induction chemoimmunotherapy.

FCA: forget chemoimmunotherapy with alemtuzumab?

The monoclonal antibody targeting CD52, alemtuzumab, has a more potent antileukemic activity compared with the antibody targeting CD20, rituximab. CLL cells express more CD52 than CD20.3 Finally, the combination of fludarabine with alemtuzumab (FA) was shown to be effective and safe.4,5 Hence, it seemed a logical step to combine alemtuzumab with FC chemotherapy, the most efficient backbone of c...

Chemoimmunotherapy for advanced gastrointestinal carcinomas

The combination of a single low dose of cyclophosphamide (Cy) with the adenovirus-mediated gene transfer of interleukin-12 (AdIL-12) might represent a successful therapy for experimental gastrointestinal tumors. This approach has been proven to revert immunosuppressive mechanisms elicited by cancer cells and to synergistically promote antitumor immunity. In addition, this therapeutic regimen ha...

Chemoimmunotherapy of murine mammary adenocarcinomas.

Breast cancer is the most common form of noncutaneous malignancy in the United States. Since a plateau seems to have been reached in the efficacy of conventional therapy for this, as well as for other solid tumors, our laboratory has been studying the therapeutic potential of chemoimmunotherapy against the disease. Here we report on attempts to treat autochthonous mammary adenocarcinomas in C3H...

Chemoimmunotherapy as a Novel Cancer Therapy

Over the past decade, it was widely accepted that some chemotherapeutic drugs can be combined with immunotherapeutic drugs in treatment of cancer. Chemotherapeutic drugs can induce apoptosis in the tumor cell and at the same time stimulate the immune response. Several reports support the use   immunomodulators in treatment of cancers through regulating the immune response and boosting the micro...